Marketer with over 20 years of experience selected to head up marketing at Predictive Oncology
Predictive Oncology (NASDAQ: POAI) has appointed Theresa Ferguson as Senior Director of Marketing. This role is pivotal as the company moves toward commercializing its AI-driven technologies aimed at developing personalized cancer therapies. Ferguson's expertise in marketing and public relations will support and guide strategic initiatives to enhance the company's market presence and profitability. CEO J. Melville Engle emphasizes this appointment as a step towards achieving sales and marketing traction in core markets, reflecting the company’s commitment to business growth.
- Appointment of Theresa Ferguson as Senior Director of Marketing to enhance marketing strategies.
- Her previous experience includes strategic roles at CVS Health/Aetna, indicating a strong marketing background.
- Focus on commercialization of AI technologies for personalized cancer therapy, potentially increasing market share.
- None.
EAGAN, Minn., April 26, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced that Theresa Ferguson has been named Senior Director of Marketing. As Predictive Oncology’s senior marketing leader, Ferguson steps in as the company begins commercialization of its knowledge-driven technologies, applying artificial intelligence (AI) to develop personalized cancer therapies and improve patient outcomes.
Ferguson will play a critical role in the development and execution of successful marketing and communications strategies to unify and strengthen Predictive Oncology’s public presence, manage corporate partners to support sales goals and help maximize profitability. She will guide ongoing strategic, operational and financial planning for existing and new key markets.
“This appointment reflects our continued commitment to gaining sales and marketing traction as we begin commercialization within our core markets,” says J. Melville (“Mel”) Engle, Chief Executive Officer and Chairman of the Board for Predictive Oncology. “Theresa brings the drive, strategic marketing insights and entrepreneurial spirit we need to help elevate and propel our business growth forward.”
Ferguson brings a diverse background of marketing, public relations and brand strategy experience that spans across agencies, corporations and nonprofits in both business-to-business and business-to-consumer settings. Most recently with CVS Health/Aetna, she worked in strategic marketing communications for Sales Enablement and was a key member of the company’s cross-enterprise Strategic Solutions Win Room team. Her integrated marketing experience includes heading up marketing for the National Women’s Soccer League, managing public relations for retail companies like the Sears Holdings hardlines business, helping to launch well-known brands in the consumer packaged goods space and marketing for various healthcare organizations based in the Chicagoland area.
She holds a Bachelor of Science degree from Illinois State University, a Master of Arts degree from National-Louis University, is a past member of the Board of Directors with the Public Relations Society of America in Chicago where she was named “Rising Star” and is an active volunteer in her community of Wheaton, IL.
About Predictive Oncology
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven company focused on applying artificial intelligence (AI) to develop optimal cancer therapies, which can lead to more effective treatments and improved patient outcomes. Through AI, Predictive Oncology uses a database of 150,000+ cancer tumors, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of success.
Public Relations Contact:
Predictive Oncology
Theresa Ferguson
630-566-2003
tferguson@predictive-oncology.com
Investor Relations Contact:
Landon Capital
Keith Pinder
(404) 995-6671
kpinder@landoncapital.net
Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b4daec2d-7172-49e8-9675-e97531395e20
FAQ
What is Predictive Oncology's recent announcement about?
How can Theresa Ferguson contribute to Predictive Oncology?
What are the goals of Predictive Oncology with its new marketing strategy?
What experience does Theresa Ferguson bring to Predictive Oncology?
What is the significance of this leadership change for POAI stock?
